Corporate Events

Dexerials Corporation, ¥ 32.0, Cash Dividend, Sep-29-2026

Dexerials Corporation, Q1 2027 Earnings Call, Aug 05, 2026

Dexerials Corporation, Board Meeting, Jun 23, 2026. Agenda: To consider and approve that the Disposition of Treasury Stock as Restricted Stock Remuneration; and to consider and approve other business related matters.

Dexerials Corporation announced that they will report Q1, 2027 results at 3:30 PM, Tokyo Standard Time on Aug 04, 2026

Dexerials Corporation proposed dividend for the full fiscal year ended March 31, 2026. For the year-end, the company proposed to pay dividend of JPY 29.00 per share against JPY 32.00 per share a year ago. Date of the annual general meeting of shareholders is June 23, 2026. Scheduled date to commence dividend payments is June 24, 2026. Effective October 1, 2024, the Company conducted a 3-for-1 split of common shares. The amount of the fiscal year-end dividend for the fiscal year ended March 31, 2025 is presented on a post-stock split basis and the total amount of annual dividends per share is not indicated. The total amount of dividends includes dividends for the shares of the Company held by Custody Bank of Japan Ltd., (Trust Account E) (JPY 435 million for the fiscal year ended March 31, 2025, and JPY 370 million for the fiscal year ended March 31, 2026).

Dexerials Corporation announced that Outside Director Satoshi Taguchi will retire at the conclusion of the annual General Meeting of Shareholders scheduled for June 23, 2026.

Dexerials Corporation provided dividend guidance for the second quarter-end and full fiscal year ending March 31, 2027. For the second quarter-end, the company expects dividend of JPY 32.00 per share against JPY 29.00 per share a year ago. For the full year, the company expects dividend of JPY 32.00 per share against JPY 29.00 per share a year ago. Effective October 1, 2024, the Company conducted a 3-for-1 split of common shares. The amount of the fiscal year-end dividend for the fiscal year ended March 31, 2025 is presented on a post-stock split basis and the total amount of annual dividends per share is not indicated. The total amount of dividends includes dividends for the shares of the Company held by Custody Bank of Japan Ltd., (Trust Account E) (JPY 435 million for the fiscal year ended March 31, 2025, and JPY 370 million for the fiscal year ended March 31, 2026).

Dexerials Corporation provided consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of JPY 123,000 million, business profit of JPY 40,000 million, operating profit of JPY 38,500 million, Profit attributable to owners of parent of JPY 27,500 million and Basic earnings per share of JPY 163.45 per share.

Dexerials Corporation, Annual General Meeting, Jun 23, 2026.

Dexerials Corporation expected to report Q1 2027 results on August 7, 2026. This event was calculated by S&P Global (Created on May 14, 2026).

Dexerials Corporation, 2026 Earnings Call, May 14, 2026

Dexerials Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 13, 2026

Dexerials Corporation reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 87,296 million compared to JPY 87,163 million a year ago. Net income was JPY 21,267 million compared to JPY 23,356 million a year ago. Basic earnings per share from continuing operations was JPY 126.23 compared to JPY 135.97 a year ago. Diluted earnings per share from continuing operations was JPY 121.25 compared to JPY 130.03 a year ago.

Dexerials Corporation, Q3 2026 Earnings Call, Feb 10, 2026

Dexerials Corporation expected to report Fiscal Year 2026 results on May 12, 2026. This event was calculated by S&P Global (Created on January 8, 2026).

From November 12, 2025 to December 18, 2025, the company has repurchased 1,677,100 shares, representing 0.99% for ¥4,999.78 million. With this, the company has completed the repurchase of 1,677,100 shares, representing 0.99% for ¥4,999.78 million under the buyback announced on November 12, 2025.

The company closed its plan on December 18, 2025.

Dexerials Corporation announced that they will report Q3, 2026 results on Feb 09, 2026

Dexerials Corporation (TSE:4980) announces a share repurchase program. Under the program, the company will repurchase 2,500,000 shares, representing 1.42% of its share capital, for ¥5,000 million. The company will repurchase its shares in order to improve capital efficiency and enhance shareholder returns as part of implementing capital policy according to the business environment in consideration of factors such as opportunities for strategic investment and the Company’s financial condition. The program will run until December 23, 2025. As of September 30, 2025, the company had 175,564,205 shares outstanding (excluding treasury shares) and 854,295 shares in treasury.

The Board of Directors of Dexerials Corporation has authorized a buyback plan on November 12, 2025.

Dexerials Corporation, ¥ 29.0, Cash Dividend, Mar-30-2026

Dexerials Corporation expected to report Q3 2026 results on February 10, 2026. This event was calculated by S&P Global (Created on November 12, 2025).

Dexerials Corporation announced cash dividend of JPY 29.00 per share for the second quarter ended September 30, 2025 as compared to dividend of JPY 78.00 per share a year ago. Effective October 1, 2024, the Company conducted a 3-for-1 split of common shares. Scheduled date to commence dividend payments: December 18, 2025.

Dexerials Corporation, Board Meeting, Nov 12, 2025. Agenda: To consider Regarding Details of Repurchase of Treasury Shares and Decision Regarding Details of Retirement of Treasury Shares.

Dexerials Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company expected net sales of JPY 114,000 million, operating profit of JPY 39,000 million, Profit attributable to owners of parent of JPY 26,000 million and Basic earnings per share of JPY 153.69 as compared to previous guidance of net sales of JPY 103,500 million, operating profit of JPY 28,000 million, Profit attributable to owners of parent of JPY 20,500 million and Basic earnings per share of JPY 120.25. Reason for the revision: During the current consolidated semi-annual period, performance exceeded expectations due to the expansion of high value-added products such as Anti-reflection films (ARF), as well as the depreciation of the yen compared to the initial exchange rate assumptions. Company has revised exchange rate assumption for the second half of the fiscal year, setting the annual rate at ¥145.8 per USD. Based on this situation, Company has upwardly revised full-year earnings forecast as stated above.

Dexerials Corporation and Veritas In Silico Inc. have been conducting Proof-of-Concept studies on the feasibility of a novel spectroscopic measurement methods for RNA structures since December 2023. As their studies have progressed and feasibility has become foreseeable, Dexerials and VIS have agreed to undertake joint technology development aimed at establishing and implementing a high-speed and high-accurate spectroscopic RNA structure measurement methods for societal application. The Joint Development aims to establish an accurate yet rapid non-destructive Spectroscopic measurement methods for RNA structure within the next three years (start date to be determined through discussions between the two companies). The Methods will complement both ambiguous structural analysis techniques like SHAPE and time-consuming structural analysis techniques like NMR for medium-length RNA strands, enabling the determination of their sequence composition, secondary structure, and tertiary structure. In the Joint Development, VIS will leverage its expertise in RNA structure to design RNA strands and perform structural analysis. Dexerials will utilize its spectroscopic instrumentation measurement technology, machine learning, and data analysis capabilities. Currently, VIS is conducting joint drug discovery research on small-molecule drugs targeting mRNA with multiple pharmaceutical companies, utilizing its proprietary drug discovery platform, ibVIS®?. This platform integrates various drug discovery technologies that are optimized for mRNA targets. This drug discovery platform is also applicable to nucleic acid drug discovery research, and VIS is already working to create its own pipeline of nucleic acid. drugs. The outcomes of this joint development are expected to enhance the robustness of ibVIS®? and lead to a deeper understanding of RNA structures. Furthermore, as the Methods is anticipated to be non-destructive, high-speed, and high-accurate, Dexerials and VIS are planning to widely release the Methods in the future. This will enable its application not only to RNA structural studies but also to quality inspection and quality control during RNA manufacturing. comments from Shingo NAKAMURA, Representative Director and CEO of VIS.VIS has been leveraging ibVIS platform to discover mRNA-targeted small molecule ®? drugs and nucleic acid therapeutics. At its core, approach involves analyzing long RNA substructures using in silico methods to identify drug-targetable substructures. While confirmed these identified substructures using techniques like NMR, recognized room for improvement in terms of speed, accuracy, and information content. The Methods are capable of rapidly and accurately obtaining a wealth of detailed information, including structural elements, for medium-length RNAs. This objective is accomplished through the training of machine learning models on data from multiple sensors that were previously utilized independently. This approach complements and improves upon the multiple measurement techniques traditionally employed. VIS will first implement these methods internally. Given the high applicability and generality of this technology, VIS also aims to commercialize the provision of these methods to generate revenue. Furthermore, VIS expects that customer usage will accumulate additional data, which will use to enhance the accuracy of the machine learning and further improve the Methods. VIS intends to stabilize and enhance business through these methods while also contributing to the scientific field. Impact on Future Business Performance of VIS. The research expenses associated with the Joint Development will be respectively covered by Dexerials and VIS, with no financial transactions planned between the parties. Therefore, VIS anticipates that the impact on business performance of VIS for the fiscal year ending December 2025 and beyond will be minimal. In case any matters requiring disclosure arise in the future, they will be promptly disclosed.

Dexerials Corporation, Q2 2026 Earnings Call, Nov 13, 2025